We are live on ! Find out more
EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

149 hedge funds and large institutions have $1.31B invested in Eagle Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 48 increasing their positions, 46 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

94% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 16

12% more call options, than puts

Call options by funds: $20.7M | Put options by funds: $18.4M

12% more capital invested

Capital invested by funds: $1.17B → $1.31B (+$136M)

9% more funds holding

Funds holding: 137 → 149 (+12)

4% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 46

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

Holders
149
Holders Change
+12
Holders Change %
+8.76%
% of All Funds
3.72%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.15%
New
31
Increased
48
Reduced
46
Closed
16
Calls
$20.7M
Puts
$18.4M
Net Calls
+$2.23M
Net Calls Change
-$8.96M

Top Buyers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
+$12.6M
2
CM
Castleark Management
Illinois
+$8.46M
3
State Street
State Street
Massachusetts
+$6.87M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.68M
5
BFA
BlackRock Fund Advisors
California
+$6.06M

Top Sellers

Rank Fund Capital Flow
1
PAI
ProQuest Associates IV
Florida
-$31.3M
2
O
OrbiMed
New York
-$26.5M
3
PC
PointState Capital
New York
-$21.3M
4
JCI
Jet Capital Investors
New York
-$9.44M
5
Morgan Stanley
Morgan Stanley
New York
-$8.74M
Name Holding Trade Value Shares
Change 		Change in
Stake
Baird Financial Group
51
Baird Financial Group
Wisconsin
$2.66M +$2.44M +33,522 New
Two Sigma Investments
52
Two Sigma Investments
New York
$2.65M +$2.43M +33,437 New
Lazard Asset Management
53
Lazard Asset Management
New York
$2.65M – – –
PNC Financial Services Group
54
PNC Financial Services Group
Pennsylvania
$2.26M -$907K -12,482 -30%
QIM
55
Quantitative Investment Management
Virginia
$2.19M +$2M +27,600 New
Bank of Montreal
56
Bank of Montreal
Ontario, Canada
$2.15M -$6.83M -93,960 -78%
TCIM
57
TIAA CREF Investment Management
New York
$2.03M -$39.9K -549 -2%
Deutsche Bank
58
Deutsche Bank
Germany
$1.98M -$3.81M -52,492 -68%
Russell Investments Group
59
Russell Investments Group
United Kingdom
$1.94M +$1.78M +24,553 New
SLG
60
Stanley-Laman Group
Pennsylvania
$1.9M – – –
NFA
61
Nationwide Fund Advisors
Ohio
$1.58M -$86.1K -1,185 -6%
AQR Capital Management
62
AQR Capital Management
Connecticut
$1.57M -$5.16K -71 -0.4%
UBS Group
63
UBS Group
Switzerland
$1.56M +$1.12M +15,469 +367%
EIM
64
Essex Investment Management
Massachusetts
$1.55M +$369K +5,082 +35%
California State Teachers Retirement System (CalSTRS)
65
California State Teachers Retirement System (CalSTRS)
California
$1.45M -$36.3K -500 -3%
CCM
66
Corsair Capital Management
New York
$1.44M -$34.4K -473 -3%
Wells Fargo
67
Wells Fargo
California
$1.39M +$811K +11,166 +175%
New York State Common Retirement Fund
68
New York State Common Retirement Fund
New York
$1.39M +$586K +8,067 +86%
PPA
69
Parametric Portfolio Associates
Washington
$1.32M +$915K +12,592 +311%
Prudential Financial
70
Prudential Financial
New Jersey
$1.26M +$94.7K +1,304 +9%
AllianceBernstein
71
AllianceBernstein
Tennessee
$1.24M – – –
TA
72
Teachers Advisors
New York
$1.23M +$54.6K +752 +5%
Swiss National Bank
73
Swiss National Bank
Switzerland
$1.22M +$65.4K +900 +6%
BG
74
BlackRock Group
United Kingdom
$1.18M +$367K +5,055 +52%
Bank of America
75
Bank of America
North Carolina
$1.15M +$930K +12,808 +789%
1 2
3
4 5

EGRX Hedge Fund Activity: Q4 2016 in Review

149 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q4 2016, worth a combined $1.31B — up 12% from $1.17B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new EGRX positions and 16 closed out — a net gain of 15 holders — while 48 added to existing stakes and 46 trimmed.

The largest buyer was Victory Capital Management, adding an estimated $12.6M. The largest seller was ProQuest Associates IV, cutting an estimated $31.3M.

  • 149 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q4 2016, up from 137 in Q3 2016.
  • Funds reported $1.31B of Eagle Pharmaceuticals, Inc. stock for Q4 2016, up 12% quarter-over-quarter.
  • 31 funds opened new Eagle Pharmaceuticals, Inc. positions in Q4 2016 and 16 closed out, a net change of +15 holders.
  • The largest Eagle Pharmaceuticals, Inc. buyer in Q4 2016 was Victory Capital Management, an estimated $12.6M added.
  • The largest Eagle Pharmaceuticals, Inc. seller in Q4 2016 was ProQuest Associates IV, an estimated $31.3M sold.

Based on aggregated 13F filings for Q4 2016.